Although recent studies have indicated roles of long non-coding RNAs (lncRNAs) in physiological aspects of cell-type determination and tissue homeostasis 1 , their potential involvement in regulated gene transcription programs remains rather poorly understood. The androgen receptor regulates a large repertoire of genes central to the identity and behaviour of prostate cancer cells 2 , and functions in a ligand-independent fashion in many prostate cancers when they become hormone refractory after initial androgen deprivation therapy 3 .
Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptormediated gene activation programs and proliferation in prostate cancer cells. Binding of PRNCR1 to the carboxy-terminally acetylated androgen receptor on enhancers and its association with DOT1L appear to be required for recruitment of the second lncRNA, PCGEM1, to the androgen receptor amino terminus that is methylated by DOT1L. Unexpectedly, recognition of specific protein marks by PCGEM1recruited pygopus 2 PHD domain enhances selective looping of androgen-receptor-bound enhancers to target gene promoters in these cells. In 'resistant' prostate cancer cells, these overexpressed lncRNAs can interact with, and are required for, the robust activation of both truncated and full-length androgen receptor, causing ligand-independent activation of the androgen receptor transcriptional program and cell proliferation. Conditionally expressed short hairpin RNA targeting these lncRNAs in castration-resistant prostate cancer cell lines strongly suppressed tumour xenograft growth in vivo. Together, these results indicate that these overexpressed lncRNAs can potentially serve as a required component of castrationresistance in prostatic tumours.
One of the overexpressed lncRNAs in prostate cancer, PCGEM1, is tissue-specific and correlated with high-risk prostate cancer patients, including African-American men 4 , whereas a second highly expressed lncRNA, PRNCR1 (PCAT8), is pervasively transcribed from the 8q24 'gene desert' region in strong association with susceptibility of prostate cancer 5 . Paired benign prostatic hyperplasia and aggressive tumour specimens (Gleason scores 3 1 3) derived from three individual prostate cancer patients exhibited .100-fold upregulation of PRNCR1 and PCGEM1 expression ( Supplementary Fig. 1a, b ). Native RNA immunoprecipitation (RIP) experiments in paired prostate tumour and benign prostatic hyperplasia tissues (Gleason scores 2 1 3 to 4 1 3), revealed a specific association of full-length androgen receptor (AR) with both PRNCR1 and PCGEM1 in prostate tumour tissues ( Fig. 1a, b ; Supplementary Fig. 1a , c) compared to minimal interactions with glucocorticoid receptor ( Supplementary Fig. 1c and data not shown). In prostate cancer LNCaP cells, dihydrotestosterone (DHT) treatment induced association of AR with both PRNCR1 and PCGEM1 (Fig. 1c ), but not with NEAT2 (also known as MALAT1) (Fig. 1c ). Antisense oligonucleotide (ASO)-based knockdown of PRNCR1 abolished both AR-PRNCR1 and AR-PCGEM1 interactions, whereas knockdown of PCGEM1 did not affect the AR-PRNCR1 interaction ( Fig. 1d ; Supplementary Fig. 2a ), indicating the PRNCR1-dependent recruitment of PCGEM1.
Knockdown of either PRNCR1 or PCGEM1 resulted in a significant decrease in DHT-induced activation of canonical AR target genes while not affecting AR levels ( Supplementary Fig. 2a -c). Global run-on sequencing (GRO-Seq) confirmed that knockdown of either PRNCR1 or PCGEM1 significantly decreased the induction of 617 DHT-upregulated genes (n 5 617, edgeR false discovery rate (FDR) , 0.01, and read density (RD) . 2) with AR-bound enhancers within 200 kilobases (kb) ( Fig. 1e ), but had no effect on DHT-unresponsive genes located .200 kb away from AR-bound enhancers ( Supplementary Fig. 2d ), verified by randomly extracting sets of 1,000 genes (data not shown).
Using chromatin isolation by RNA purification (ChIRP) 6 with biotin-labelled DNA probes (40-60 nucleotides) tiling PRNCR1 and PCGEM1 RNAs ( Supplementary Fig. 3a -c), we identified 2,142 highconfidence PCGEM1 occupancy sites genome-wide ( Supplementary  Fig. 3d , e) and motif analysis uncovered a very significantly enriched AR response element (ARE) DNA motif ( Supplementary Fig. 3f ), revealing that ,82% of PCGEM1 co-localized with AR-bound sites (6 3 kb relative to the centre of PCGEM1 peak), of which ,70% corresponded to AR bound, H3K4me1-marked enhancers (Fig. 1f , g and Supplementary Fig. 3g ), independently confirmed by quantitative (qPCR) analyses ( Supplementary Fig. 3h , i) and ChIRP-Seq using even-numbered and odd-numbered probe sets ( Supplementary Fig. 3j and data not shown). These data indicate a stoichiometry of PCGEM1 sufficient to account for the recruitment to AR DNA regulatory binding sites on enhancers. Levels of PRNCR1 in LNCaP cells are estimated as ,400-600 copies per cell (data not shown). The ability of these lncRNAs to read enhancer-associated histone marks might account for their preferential presence at AR-bound enhancers (see below).
By imposing a high stringency wash condition, we identified that DOT1L, CARM1, GADD45a and AR specifically associated with in vitro transcribed biotinylated PRNCR1 by mass spectrometry analysis, whereas AR, b-catenin and pygopus 2 (PYGO2) preferentially associated with in vitro transcribed biotinylated PCGEM1 ( Supplementary  Fig. 4a -c; Supplementary Tables 1-3) . b-catenin, CARM1 and GADD45a have been suggested to have important roles in AR signalling 7 . Knockdown of AR, DOT1L, CTNNB1 and PYGO2 by specific siRNAs impaired DHT-induced activation of AR target genes, TMPRSS2, PSA (also known as KLK3) and FKBP5 ( Supplementary Fig. 4d ). Mass spectrometry analysis revealed that the lncRNA-bound AR contains several post-translational modifications, including K631/634 acetylation and K349 methylation ( Supplementary Fig. 4e ; Supplementary Tables 1-3) . Consistent with the proposed importance of acetylation of AR in activation of an AR target gene 8 , a K631/634R mutation on AR inhibited its interaction with PRNCR1 and PCGEM1 ( Fig. 2a; Supplementary Fig. 5a ) and DHT-induced expression of AR target genes ( Supplementary Fig. 5b ), whereas overexpression of an AR(K631/634Q) mutant resulted in enhanced DHT-dependent interactions with PRNCR1 and PCGEM1 ( Fig. 2a, b ; Supplementary Fig. 5c ). These data indicate that PRNCR1 and PCGEM1 interact with AR in a K631/634 acetylation-and K349 methylation-dependent manner, respectively.
Because effective AR-PCGEM1 interaction requires the methylation of AR at K349 ( Fig. 2b) , we confirmed DOT1L-mediated AR methylation at K349 using in vitro methylation assays, finding that a K349R point mutation markedly inhibited AR methylation (Supplementary 6a; Fig. 2c ). Specific DOT1L knockdown impaired the interaction between AR and PCGEM1, but not that with PRNCR1 (Supplementary Fig. 6b , c), indicating that AR K349 methylation, mediated by PRNCR1-bound DOT1L, is critical for the recruitment of PCGEM1 to AR. Indeed, overexpression of an AR(K349R) mutant significantly reduced DHT-induced gene activation in LNCaP cells ( Supplementary  Fig. 5b) .
In vitro binding studies demonstrated that PRNCR1 bound to the region of amino acids 549-623 of AR and PCGEM1 bound to the AR N-terminal region when methylated at K349 by overexpressed DOT1L ( Fig. 2d , e; Supplementary Fig. 7a ). By incubating in vitro transcribed PCGEM1 with nuclear lysate from cells overexpressing Myc-tagged PYGO2 proteins, including full-length, N-or C-terminally truncated proteins, we identified strong interactions between PCGEM1 and the PYGO2 C terminus ( Supplementary Fig. 7b ).
To map the sequence motif of PCGEM1 responsible for AR or PYGO2 binding, we performed modified in vitro RNA pull-down followed by dot-blot assay ( Supplementary Fig. 8a ), using two regions of NEAT2 bound by unmethylated PC2 (also known as CBX4) as a Fold change (log2) 
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control for the crosslinking and immunoprecipitation (CLIP) assay 9 ( Supplementary Fig. 8b ). Methylated AR bound/protected PCGEM1 sequence was identified to encompass 421-GAT…TCC-480 (Supplementary Fig. 8c ), with unmethylated AR or the unrelated protein His-tagged MURF1 (also known as TRIM63) not showing specific binding to any region of PCGEM1 ( Supplementary Fig. 8c ). A sequence motif of PCGEM1 encompassing 1201-TGT…ATT-1260, distinct from the AR binding region, was identified as the PYGO2 binding motif, with deletion of this motif (D1191-1270) abolishing PYGO2 binding with no effect on AR binding ( Supplementary Fig. 8c and Fig. 2f ). Similarly, deletion of the AR binding site of PCGEM1(D411-490) abolished the AR-PCGEM1 interaction, with minimal effect on the PYGO2-PCGEM1 interaction (Fig. 2f ).
Modified histone peptide array experiments using in vitro transcribed biotinylated PCGEM1 or PRNCR1 revealed that they selectively recognize H3K4me1 and H4K16ac histone marks indicative of enhancers 10, 11 , respectively ( Supplementary Fig. 9a -c). Therefore, it is probable that these histone tail associations of PRNCR1 and PCGEM1 serve as a functional component of their preferred recruitment to enhancers of AR-regulated transcription units.
PCGEM1 and PRNCR1 were highly upregulated in the LNCaP-cds2 and CWR22Rv1 castration-resistant prostate cancer cell line models compared with immortalized 'normal' prostate epithelial cell lines, WPE and RWPE, or even LNCaP cells ( Supplementary Fig. 10a , b). The AR antagonist, bicalutamide (Casodex), reduced the DHT-induced PSA expression in LNCaP cells but failed to act as an antagonist in LNCaP-cds2 cells ( Supplementary Fig. 10c ). Transduction of LNCaP-cds2 cells with lentivirus expressing short hairpin RNAs (shRNAs) against PRNCR1 or PCGEM1, but not a nonspecific (lacZ) shRNA, significantly reduced the activation of several canonical AR target genes but had no effect on AR expression levels (Supplementary Figs 10d-f and 11a). Because truncated forms of AR that exhibit ligandindependent transcriptional activation are frequently detected in castrationresistant prostate cancer and may often reflect alterations in AR gene structure, we investigated the potential roles of PRNCR1 and PCGEM1 in AR-mediated basal transcription activity in castration-resistance prostate cancer cells. RT-PCR (PCR with reverse transcription) using primers specific for one AR 'splicing' variant, which encodes a truncated length AR known as AR-V7 (ref. 12) confirmed the presence of this variant in LNCaP-cds2 cells ( Supplementary Fig. 11b ). Western blot analysis using N-terminal AR-specific antibody (441), revealed that the AR-V7 variant (,75 kilodaltons (kDa)) represents ,1-2% of total AR in LNCaP-cds2 cells, although it is the predominant form in CWR22Rv1 cells ( Supplementary Fig. 10g ). Because overexpression of truncated AR can constitutively activate androgen-responsive genes in the absence of ligand 12 , we transfected LNCaP cells with the AR(Q641X) mutant, with activation of canonical androgen-responsive genes, including TMPRSS2, PSA, KLK2, FKBP5 and NKX3-1 in the absence of added androgen ( Fig. 3a ; Supplementary Fig. 12a, b ). This constitutive effect of AR(Q641X) was highly reduced upon knockdown of either PRNCR1 or PCGEM1 (Fig. 3a ). An RNA immunoprecipitation (RIP) assay in CWR22Rv1 cells demonstrated that both PRNCR1 and PCGEM1 associated constitutively with truncated AR (AR-V7) with or without ligand (Fig. 3b ). By immunoblotting the AR-V7 immunoprecipitates with N-terminal AR-specific antibody (441), we did not observe any residual pull-down indicative of interaction between full-length and truncated AR (Fig. 3b , right panel), arguing against an indirect association of PRNCR1 and PCGEM1 with truncated AR because of heterodimerization with full-length AR. Using an antibody specific for the C-terminal ligand binding domain of AR (C-19) to selectively recognize full-length AR, we observed interactions between these lncRNAs and full-length AR in the absence of added ligand (Fig. 3b) , possibly due to the relative higher level of basal acetylation and methylation of full-length AR in CWR22Rv1 cells ( Supplementary Fig. 12c ).
To study the biological roles of PRNCR1 or PCGEM1, we generated stable cell lines derived from CWR22Rv1 harbouring doxycycline (dox)-induced shRNA against lacZ, PRNCR1 or PCGEM1 (Supplementary Fig. 13a ). Dox-induced either PCGEM1 or PRNCR1 knockdown significantly reduced the expression of canonical AR target genes, with no noticeable effect on AR expression level ( Supplementary Figs 11a,  13b ). Dox-induced knockdown of either PRNCR1 or PCGEM1 also inhibited the growth of CWR22Rv1 cells comparable to the effect of AR knockdown 13 , without affecting AR expression levels ( Fig. 3c ; Supplementary Figs 11a and 13c). Remarkably, conditional shRNA-mediated inhibition of either PRNCR1 or PCGEM1 robustly inhibited in vivo tumour growth in a CWR22Rv1 prostate cancer xenograft mouse model (Fig. 3d) , indicative of an lncRNA-dependent regulatory network that critically regulates growth of castration-resistant prostate cancer cells in vivo.
Although knockdown of either PRNCR1 or PCGEM1 did not affect the recruitment of AR on PSA and KLK2 enhancers (Supplementary Fig. 14a, b , left panels), knockdown of PCGEM1 inhibited SMC1 recruitment on PSA and KLK2 promoters, with only minimal effects on SMC1 levels on enhancers ( Supplementary Fig. 14a , b, right panels), consistent with proposed cohesin-dependent 14 formation of chromatin loops between enhancers and promoters. We further demonstrated ligandinduced enhancer-promoter interactions in the PSA transcription unit by chromatin immunoprecipitation (ChIP)-3C (3C, chromosome conformation capture) assay 15 and found that these interactions were impaired by depletion of either PRNCR1 or PCGEM1 (Fig. 4a ; Supplementary Fig. 14c ). The ability of PYGO2, associated with PCGEM1 ( Supplementary  Fig. 2a ), to recognize a canonical promoter histone mark 16 , H3K4me3, raised the possibility that PYGO2 might be involved, at least quantitatively, in enhancer-promoter looping. ChIP assays revealed that PYGO2 was efficiently recruited to enhancer and promoter regions of the PSA, KLK2 and TMPRSS2 transcription units in a DHT-dependent manner, exhibiting relatively higher and earlier association with the enhancer regions ( Fig. 4b; Supplementary Fig. 15a ). Knockdown of either PRNCR1 or PCGEM1 in LNCaP cells inhibited PYGO2 recruitment to AR-dependent enhancers/promoters ( Fig. 4c; Supplementary Fig. 15b ). On knockdown of PYGO2, AR and SMC1 failed to effectively associate with the PSA, KLK2 or TMPRSS2 promoters despite unperturbed DHTdependent AR or SMC1 recruitment to their enhancers (Supplementary Fig. 16a-d) and DHT-induced enhancer-promoter looping in the PSA transcription unit was inhibited ( Fig. 4d ). GRO-Seq analysis revealed a broad inhibition of AR-dependent transcriptional program under the condition of PYGO2 knockdown (n 5 290, edgeR FDR , 0.01), which did not affect AR expression ( Fig. 4e; Supplementary Fig. 16a ).
Depleting PRNCR1 or PCGEM1 from LNCaP-cds2 cells also inhibited enhancer-promoter looping in FASN and NDRG1 ( Supplementary  Fig. 17a-d; Fig. 4f ), previously shown to be activated following FoxA1 knockdown in LNCaP cells 17 . Again, knockdown of either PRNCR1 or PCGEM1 had no effect on recruitment of AR to enhancer regions of the FASN and NDRG1 transcription units or on PYGO2 expression levels ( Supplementary Fig. 17e ).
To address whether the PYGO2 PHD domain might itself be instrumental for its function in mediating chromatin looping, we first depleted PYGO2 by shRNA treatment followed by overexpression in 
LNCaP-cds2 cells of either shRNA-resistant wild-type PYGO2 (ref.
18) or a W352A mutant defective for H3K4me3 recognition 16 . In 3C assays, knockdown of PYGO2 reduced FASN enhancer-promoter interactions, which could be rescued by overexpression of wild-type, but not W352A, PYGO2 ( Supplementary Figs 18a and 19a ), even though there was equal recruitment of wild-type PYGO2 or the W352A mutant to enhancers, and no altered promoter H3K4me3 levels (Supplementary Fig. 18b-d) . Knockdown of PYGO2 curtailed the expression of canonical AR target genes TMPRSS2, KLK2, PSA, FKBP5 and NKX3-1, and overexpression of wild-type, but not W352A, PYGO2 was able to robustly rescue the induction of these genes (Supplementary Fig. 19b ). These data indicate that PYGO2 exerts a quantitatively important role in DHT-dependent enhancer-promoter interactions and coding target gene activation. For 220 AR-regulated coding gene promoters under regulation of an enhancer we observed recruitment of PYGO2 by ChIP followed by high-throughput sequencing (ChIP-Seq), but did not observe ligand-induced increase in the next adjacent, non-AR-regulated transcription unit (,204 promoters) ( Supplementary  Fig. 19c) ; indicating that the H3K4me3 mark cannot alone be sufficient to effectively recruit PYGO2 and suggesting a role for other similarly modified proteins in prostate cancer cell gene activation events.
In the present study, we have found a mechanistic link between prostate cancer-upregulated lncRNAs and AR transcriptional activity, revealing the biological importance of the lncRNAs, PRNCR1 and PCGEM1, in licensing C-terminally truncated, as well as full-length, ARdependent gene activation events in prostate cancer cells (Supplementary Fig. 19d ). Considering the regulatory potential of enhancer-derived RNAs identified in recent studies 19, 20 , lncRNAs may also be part of a broad transcription regulatory network.
METHODS SUMMARY
Experiments were performed in LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1, WPE and RWPE cells. ChIRP-Seq, GRO-Seq, ChIP-Seq, ChIP-3C and 3C assays were performed as described 6, 15, 17 with modifications (details in Methods section). All siRNAs used in this study were either validated by vendors (Dharmacon, Qiagen and Sigma-Aldrich) or by our in-house RT-qPCR/western blotting analyses for specificity ( Supplementary Figs 6b and 16a ) and used only if providing .70% knockdown efficiency. Antisense oligonucleotides were designed and synthesized by IDT, with knockdown specificity and efficiency of 3 individual sequences tested for PRNCR1 or PCGEM1 ( Supplementary Fig. 2a ). shRNAs against PRNCR1 and PCGEM1 were designed at http://biosettia.com/support/shrna-designer, with knockdown specificity and efficiency of 2 individual sequences tested for PRNCR1 or PCGEM1 ( Supplementary Fig. 10d ). ChIRP probes were designed at http://www. singlemoleculefish.com/designer.html. Relative quantities of gene expression level were normalized to the actin gene. The relative quantities of ChIP samples were normalized by individual inputs, respectively. Results are reported as mean 6 s.e.m. of three or six independent experiments as indicated. Comparisons were performed using a two-tailed paired Student's t-test.
METHODS
Tissue samples and processing. Experiments using paired benign prostatic hyperplasia (BPT) and tumour (T) were performed from unidentified individual prostate cancer patients, which were obtained from R. W. deVere White, UC Davis Comprehensive Cancer Center. Informed consent was obtained from all subjects. The tissue samples used in this manuscript were received as de-identified samples without any protected health information (PHI) attached. The Gleason score or tumour/BPH status was considered pathological information, not patient information. We did not know the sample donors' names or birth dates. The tissues were homogenized by Precellys24 tissue homogenizer followed by downstream assays. Cell culture and transfection. Prostate cancer LNCaP cells were obtained from ATCC and cultured in RPMI1640 containing 10% (vol/vol) FBS. The benign immortalized prostate cell line RWPE, WPE and the castration-resistant prostate cancer cell lines LNCaP-cds1, LNCaP-cds2, CWR22Rv1 were provided by C. Evans. RWPE and WEP cells were grown in KGM media and BulletKit from Lonza supplemented with L-Glutamine. CWR22Rv1, LNCaP-cds1 and LNCaP-cds2 cells were grown in RPMI1640 media containing 5% final volume of charcoal stripped serum. LNCaP cells were grown to 30-50% confluence and siRNA/ASO transfections were carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Transfection of LNCaP cells with DNA plasmids was performed using Amaxa Nucleofector Kit R from Lonza. shRNAs specific for lacZ, PRNCR1, PCGEM1 or AR were delivered, by lentiviral transduction, to LNCaP-cds2 and CWR22Rv1 cells. Cloning procedures. The full-length AR expression vector has been previously described 17 . Human PCGEM1 (14-1556) and PRNCR1 fragments (1-3240, 3156-6428, 6331-9670 and 9531-12710) were amplified from complementary DNAs (cDNAs) generated from LNCaP cells and cloned into pSTBlue-1 vector (Novagen) for in vitro transcription assay. The PCGEM1 gene sequence with 411-490 and 1191-1270 deletion were synthesized by GeneScript and cloned into pcDNA3.1 vector (Invitrogen). Lentiviral vector pLKO.1 containing the shRNA against scrambled sequence, PYGO2 and pHIV vector containing RNAi-resistant PYGO2 cDNA were obtained from X. Dai (Department of Biological Chemistry, University of California at Irvine) 18 . A 4.8 kb genomic sequence upstream of the PSA promoter was amplified from LNCaP cells and subcloned into pSTBlue-1 vector (Novagen). Bacterial expression vectors for AR and K349R mutant were constructed by subcloning the gene sequences into pET-28a backbone (Novagen). Nuclear expression vectors for AR(2-920), AR(2-548), AR(549-920), AR(2-623), AR(549-623), AR(624-666), AR(667-920) and PYGO2(2-406), PYGO2(2-266), PYGO2(267-406) were constructed by subcloning the cDNA sequences into pCMV/myc/nuc backbone (Invitrogen). The expression vector of Flag-DOT1L was provided by Y. Zhang's laboratory. All mutants were generated using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Detailed oligonucleotide sequences are listed in the oligonucleotide sequences and primers section. Antisense DNA oligonucleotide, siRNA and lentiviral shRNA. 2'-O-methyl phosphor-othioate oligonucleotides were designed and synthesized by Integrated DNA Technologies. Commercially available FlexiTube siRNA targeting AR (SI02757258) and CARM1 (SI02663815) from Qiagen, ON-TARGETplus SMARTpool siRNA targeting DOT1L (L-014900-01-0005) and GADD45a (L-003893-00-0005) from Dharmacon, MISSION siRNA targeting b-catenin (SASI_Hs01_00117958), Pygopus 2 (SASI_Hs01_00059018) from Sigma-Aldrich were used in this study. The knockdown efficiency and specificity of all siRNAs were validated either by vendors or ourselves ( Supplementary Fig. 6b, 16a ). Oligonucleotides for shRNA targeting PRNCR1, PCGEM1 and AR were designed at (http://biosettia.com/support/shrna-designer) and cloned into pLV-H1TetO-GFP-Puro vector according to the manufacturer's instructions (Biosettia). We tested the efficacy and specificity of 3 ASOs (see Supplementary Fig. 2a ) and 2 shRNAs (see Supplementary Fig. 10d ) in LNCaP and LNCa-cds2 cells, respectively, for both PRNCR1 and PCGEM1. For functional assays, the specific ASO/shRNA giving the best knockdown efficiency was used. Detailed ASO/shRNA sequences are listed in the oligonucleotide sequences and primers section. Antibodies. Specific antibodies were purchased from the following commercial sources: anti-AR (N-20), anti-AR (C-19), anti-AR (441), anti-GR (E-20), anti-bcatenin (D-10) and anti-GAPDH (6C5) from Santa Cruz Biotechnology; anti-CARM1 (4438), anti-GADD45a (3518) and anti-pan acetylated-lysine (#9441) from Cell Signaling Technology; anti-Flag M2, anti-c-Tubulin (T5326) and anti-PYGO2 from Sigma-Aldrich Prestige Antibodies; anti-PYGO2 (GTX119726) from GeneTex; Anti-DOT1L (39954) and anti-Myc tag (clone 4E12) from Active Motif; anti-SMC1 (A300-055A) from Bethyl Laboratories; anti-pan methylated lysine (7315) from Abcam and anti-AR-V7 from Precision Antibody. Protein recombination and purification. Recombinant His-AR proteins were expressed in E.coli strain BL21-CodonPlus (DE3)-RIPL (Agilent Technologies) and purified using TALON Metal Affinity Resin (Clontech). Recombinant histone H3 was purchased from Active Motif. Human DOT1L (amino acids 2-416) was obtained from Sigma-Aldrich. Human PYGO2 was purchased from BioClone. His-tagged MURF1 was purchased from BostonBiochem. RIP. RIP was performed in native conditions as described 21 . Briefly, 1 3 10 7 LNCaP cell nuclei were pelleted and lysed in 1 ml ice-cold polysomal lysis buffer (100 mM KCl, 5 mM MgCl 2 , 10 mM HEPES pH 7.0, 0.5% NP-40, 1 mM DTT (dithiothreitol)) supplemented with anti-RNase, protease inhibitor cocktail, phosphatase inhibitor cocktail, panobinostat and methylstat. The lysate were passed through a 27.5 gauge needle 4 times to promote nuclear lysis. Turbo DNase (400 U) was then added to the lysate and incubated on ice for 30 min. The cell lysate was diluted in the NT2 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 0.05% NP-40) and 50 ml of the supernatant was saved as input for PCR analysis. 500 ml of the supernatant was incubated with 4 mg of AR (441) antibodies-IgG magnetic beads (pre-blocked by 13 PBS 1 5 mg ml 21 BSA) at 4 uC overnight. The RNA/antibody complex was washed four times (1 ml wash, 5 min each) by NT2 buffer supplemented with anti-RNase, protease inhibitor cocktail, phosphatase inhibitor cocktail, panobinostat and methylstat. The RNA was extracted using acid-phenol: chloroform, pH 4.5 (with IAA, 125:24:1) (Invitrogen) according to the manufacturer's protocol and subjected to RT-qPCR analysis. ChIRP. ChIRP was performed as described 6 with minor modifications. Briefly, 60mer antisense DNA probes targeting PRNCR1 and PCGEM1 full-length sequences were designed at http://www.singlemoleculefish.com/designer.html. A set of probes targeting lacZ RNA was also designed as the negative control. All probes were biotinylated using Label IT nucleic acid biotin labelling kit from Mirus Biotechnology. LNCaP cells were fixed with 1% formaldehyde for 10 min at room temperature. Crosslinking was then quenched with 125 mM glycine for 5 min. The chromatin preparation, hybridization/elution, deep sequencing steps were essentially performed as described 4 except that the wash was conducted at 50 uC and 65 uC. The image analysis and base calling were performed using Illumina's computational analysis pipeline. The sequencing reads were aligned to hg18 human genome by using Bowtie2 (ref. 22 ) and only one read per position was kept for downstream analyses. Peak finding was performed by using HOMER suite 23 and the peaks within 1 kb from each other were merged. Peak intersection was computed by using intersectBed in BedTools 24 , after extending the peaks with 1 kb. In order to call reliable peaks, we have excluded from analysis the peaks that overlapped the satellite repeats or lacZ ChIRP peaks. The annotation of the peaks on the human genome and the tag density profiles were computed in HOMER, and the display of the heatmap were carried in MeV 25 . Sequenced motif enrichment analysis was carried in HOMER. For ChIP-Seq data (AR and H3K4me1), peak finding was performed by using HOMER or SICER 26 . Data processing procedure for overlapping ChIP-Seq and ChIRP-Seq. We used the standard ChIP-Seq peak finding tools in the processing of ChIRP-Seq data. We chose HOMER software suite (http://biowhat.ucsd.edu/homer/) for the analysis of both AR ChIP-Seq and PCGEM1 ChIRP-Seq data, using the same program routine (that is, findPeaks command) and the same default parameters that calls only the robust peaks (these parameters are outlined below): (1) fold enrichment over input tag count, default: 4.0; (2) Poisson P value threshold relative to input tag count, default: 0.0001; (3) fold enrichment over local tag count, default: 4.0; (4) fdr ,#. false discovery rate, default 5 0.001; and (5) size of region used for local filtering 5 10000. Peak finding procedure: (1) typically, the tag distribution along the genome could be modelled by a Poisson distribution and the peak finding algorithm slides windows of fixed size across the genome to find candidate peaks with a significant tag enrichment (Poisson distribution P value default 10-4 to 10-5); (2) we use very strict parameters in HOMER to call a peak: a very low FDR (that is, 0.001), and a high fold enrichment over input tag count (that is, 4). By default, HOMER also requires the tag density at peaks to be fourfold greater than in the surrounding 10 kb region. Therefore, we ensure that only the sharp peaks with low local background are called and considered for downstream analyses. Both ChIP-Seq and ChIRP-Seq data were processed precisely in the same way using the same default settings of HOMER.
For the analysis of overlapping between ChIP-Seq and ChIRP-Seq data, we used the following samples: PCGEM1 ChIRP-Seq (2DHT), PCGEM1 ChIRP-Seq (1DHT) and AR ChIP-Seq (at a higher sequencing depth). The heatmaps were generated in two steps. First, we used HOMER and the command (annotatePeaks.pl , peak file. ,genome. -size ,#. -hist ,#. -ghist) that specifies the list of peaks (,peak file.), and the tag density in a region that covers , size. kb around the peak centre; the tag density is specified in a bin size that is specified by the parameter , hist.) to generate a matrix of tag densities across the samples, for each peak. Typically the tag densities are normalized to 10 million reads for each sample. Second, we used MeV package (http://www.tm4.org/mev.html) to display the heatmap and to colour code it on a scale from 0 to 2: a difference in the colours from 2 (red) to 0 (green) may reflect a fold enrichment over local tag count. GRO-Seq. The image analysis and base calling were performed by using Illumina's standard computational analysis pipeline. Bowtie2 (ref. 22 ) was used to align the LETTER RESEARCH
